Bart Barlogie, MD, Hematology, New York, NY

BartBarlogieMD

Hematology New York, NY

Director, Multiple Myeloma Research Program

Dr. Barlogie is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Barlogie's full profile

Already have an account?

Education & Training

  • University of Heidelberg Faculty of Medicine
    University of Heidelberg Faculty of MedicineMEDICAL_SCHOOL

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2016 - 2022
  • AR State Medical License
    AR State Medical License 1989 - 2021
  • TX State Medical License
    TX State Medical License 1976 - 2005

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly, 2002-2017
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2014
  • America's Top Doctors for Cancer Castle Connolly, 2005-2013
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Analysis of the Sub-Clonal Structure of Smoldering Myeloma over Time Provides a New Means of Disease Monitoring and Highlights Evolutionary Trajectories Leading to Mye...
    Bart Barlogie, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Long-Term Outcome of Total Therapy Regimens: Impact of Molecular Subgroups
    Bart Barlogie, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • The Role of PHF19 As a Promoter of Tumorigenicity and Therapeutic Target in Multiple Myeloma
    Bart Barlogie, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

  • The Mutational Landscape of Primary Plasma Cell Leukemia 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Baseline and on-Treatment Bone Marrow Microenvironments Predict Myeloma Patient Outcomes and Inform Potential Intervention Strategies 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Longer Term Follow up of the  Randomized Phase III Trial SWOG S0777: Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) w... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Join now to see all

Press Mentions

  • Longer Term Follow-up of the Randomized Phase III Trial SWOG S0777: Bortezomib, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma Without an Intent for Immediate Autologous Stem Cell Transplant (ASCT)
    Longer Term Follow-up of the Randomized Phase III Trial SWOG S0777: Bortezomib, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma Without an Intent for Immediate Autologous Stem Cell Transplant (ASCT)May 11, 2020
  • Clinical Significance of MRD Testing in MM
    Clinical Significance of MRD Testing in MMJuly 19, 2019
  • Ex-Myeloma Unit Chief Gareth Morgan Says UAMS Audit Faulted Accounting
    Ex-Myeloma Unit Chief Gareth Morgan Says UAMS Audit Faulted AccountingMarch 04, 2019
  • Join now to see all

Professional Memberships